MA48728A - Polythérapie contre le cancer de la prostate - Google Patents

Polythérapie contre le cancer de la prostate

Info

Publication number
MA48728A
MA48728A MA048728A MA48728A MA48728A MA 48728 A MA48728 A MA 48728A MA 048728 A MA048728 A MA 048728A MA 48728 A MA48728 A MA 48728A MA 48728 A MA48728 A MA 48728A
Authority
MA
Morocco
Prior art keywords
polytherapy
prostate cancer
against prostate
cancer
prostate
Prior art date
Application number
MA048728A
Other languages
English (en)
Other versions
MA48728B1 (fr
Inventor
Linda Anne Snyder
Margaret K Yu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62067858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA48728(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA48728A publication Critical patent/MA48728A/fr
Publication of MA48728B1 publication Critical patent/MA48728B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
MA48728A 2017-04-13 2018-04-09 Niraparib, acétate d'abiratérone et prednisone pour le traitement du cancer de la prostate MA48728B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762485164P 2017-04-13 2017-04-13
PCT/US2018/026661 WO2018191141A1 (fr) 2017-04-13 2018-04-09 Polythérapie contre le cancer de la prostate

Publications (2)

Publication Number Publication Date
MA48728A true MA48728A (fr) 2020-04-08
MA48728B1 MA48728B1 (fr) 2022-10-31

Family

ID=62067858

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48728A MA48728B1 (fr) 2017-04-13 2018-04-09 Niraparib, acétate d'abiratérone et prednisone pour le traitement du cancer de la prostate

Country Status (33)

Country Link
US (4) US20180296574A1 (fr)
EP (3) EP3609497B1 (fr)
JP (3) JP7141408B2 (fr)
KR (1) KR20190134718A (fr)
CN (2) CN110753545A (fr)
AU (2) AU2018251594A1 (fr)
CA (1) CA3059562A1 (fr)
CL (1) CL2019002871A1 (fr)
CO (1) CO2019011591A2 (fr)
CR (1) CR20190467A (fr)
DK (1) DK3609497T3 (fr)
DO (1) DOP2019000264A (fr)
EA (1) EA201992430A1 (fr)
ES (1) ES2931052T3 (fr)
HR (1) HRP20221327T1 (fr)
HU (1) HUE060460T2 (fr)
IL (2) IL269879B2 (fr)
JO (1) JOP20190244A1 (fr)
LT (1) LT3609497T (fr)
MA (1) MA48728B1 (fr)
MD (1) MD3609497T2 (fr)
MX (2) MX2019012296A (fr)
MY (1) MY209010A (fr)
NI (1) NI201900105A (fr)
PE (1) PE20200444A1 (fr)
PH (1) PH12019502317A1 (fr)
PL (1) PL3609497T3 (fr)
PT (1) PT3609497T (fr)
RS (1) RS63832B1 (fr)
SG (1) SG11201909552VA (fr)
SM (1) SMT202200467T1 (fr)
UA (1) UA129514C2 (fr)
WO (1) WO2018191141A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019001224A (es) 2016-07-29 2019-06-03 Janssen Pharmaceutica Nv Metodos para tratar el cancer de prostata.
WO2020139339A1 (fr) * 2018-12-27 2020-07-02 Constellation Pharmaceuticals, Inc. Inhibiteurs de la signalisation de l'ezh2 et du récepteur des androgènes en tant qu'outils pour le ciblage du cancer de la prostate
CN116785301A (zh) 2019-09-26 2023-09-22 湖南慧泽生物医药科技有限公司 含醋酸阿比特龙的药物组合物及其制备方法和应用
JP7442328B2 (ja) * 2020-02-03 2024-03-04 株式会社三共 遊技機
CN113546037B (zh) * 2020-04-20 2024-12-27 鲁南制药集团股份有限公司 一种醋酸阿比特龙栓剂及其制备方法
UY39204A (es) * 2020-05-08 2021-11-30 Janssen Pharmaceutica Nv Formulaciones farmacéuticas de acetato de abiraterona y niraparib
MX2023011294A (es) * 2021-03-24 2023-10-05 Pfizer Combinacion de talazoparib y un antiandrogeno para el tratamiento del cancer de prostata sensible a la castracion metastasico mutado en el gen ddr.
JP7320903B2 (ja) 2021-12-15 2023-08-04 湖南慧▲澤▼生物医▲薬▼科技有限公司 アビラテロン酢酸エステルを含む組成物及び使用
CN114306236B (zh) * 2021-12-15 2022-10-21 湖南慧泽生物医药科技有限公司 用于负载醋酸阿比特龙的自微乳体系及组合物和应用
IL316019A (en) * 2022-04-07 2024-11-01 Astrazeneca Ab Combined treatment for cancer
WO2024203348A1 (fr) * 2023-03-31 2024-10-03 ソニーグループ株式会社 Procédé d'analyse de tumeurs, système d'analyse de tumeurs et procédé de génération de données d'analyse de tumeurs
WO2025027138A1 (fr) * 2023-08-02 2025-02-06 Janssen Pharmaceutica Nv Combinaison de niraparib et d'abiratérone destinée à être utilisée dans le traitement du cancer de la prostate résistant à la castration métastatique

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20130961T1 (hr) * 2006-08-25 2013-11-22 Janssen Oncology, Inc. Kombinacije za tretman raka
US20080051380A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
EP2805945B1 (fr) 2007-01-10 2019-04-03 MSD Italia S.r.l. Indazoles substitués d'amide en tant qu'inhibiteurs PARP de poly(ADP-ribose)polymérase
JP5989965B2 (ja) 2008-01-08 2016-09-07 メルク シャープ エンド ドーム リミテッド ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩
WO2012009475A1 (fr) * 2010-07-14 2012-01-19 Oregon Health & Science University Méthodes de traitement du cancer par inhibition de la déméthylase 1 spécifique de la lysine
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2014089324A1 (fr) * 2012-12-07 2014-06-12 Calitor Sciences, Llc Composés cycliques substitués et leurs procédés d'utilisation

Also Published As

Publication number Publication date
IL269879B2 (en) 2025-10-01
RS63832B1 (sr) 2023-01-31
EP3609497A1 (fr) 2020-02-19
LT3609497T (lt) 2022-12-12
AU2024202346B2 (en) 2026-01-22
JOP20190244A1 (ar) 2019-10-13
DOP2019000264A (es) 2020-07-15
CR20190467A (es) 2020-03-09
EP4176878A1 (fr) 2023-05-10
SMT202200467T1 (it) 2023-01-13
US20240245710A1 (en) 2024-07-25
US20240398837A1 (en) 2024-12-05
MX2023009569A (es) 2023-08-22
MY209010A (en) 2025-06-16
EP4176879A1 (fr) 2023-05-10
CN110753545A (zh) 2020-02-04
PT3609497T (pt) 2023-01-23
NI201900105A (es) 2020-03-11
IL320452A (en) 2025-06-01
AU2024202346A1 (en) 2024-05-02
JP7141408B2 (ja) 2022-09-22
PL3609497T3 (pl) 2023-01-23
BR112019021466A2 (pt) 2020-05-12
CA3059562A1 (fr) 2018-10-18
EA201992430A1 (ru) 2020-02-28
HRP20221327T1 (hr) 2023-03-17
JP2022141881A (ja) 2022-09-29
UA129514C2 (uk) 2025-05-21
US20180296574A1 (en) 2018-10-18
MX2019012296A (es) 2019-11-28
MD3609497T2 (ro) 2023-03-31
DK3609497T3 (da) 2022-10-31
PH12019502317A1 (en) 2020-07-06
EP3609497B1 (fr) 2022-10-12
ES2931052T3 (es) 2022-12-23
US20220175801A1 (en) 2022-06-09
JP2020516646A (ja) 2020-06-11
AU2018251594A1 (en) 2019-10-24
CN119235874A (zh) 2025-01-03
WO2018191141A1 (fr) 2018-10-18
SG11201909552VA (en) 2019-11-28
IL269879A (fr) 2019-11-28
KR20190134718A (ko) 2019-12-04
MA48728B1 (fr) 2022-10-31
JP2024023344A (ja) 2024-02-21
IL269879B1 (en) 2025-06-01
JP7407880B2 (ja) 2024-01-04
HUE060460T2 (hu) 2023-03-28
CL2019002871A1 (es) 2019-12-27
PE20200444A1 (es) 2020-02-28
CO2019011591A2 (es) 2020-02-28

Similar Documents

Publication Publication Date Title
MA48728A (fr) Polythérapie contre le cancer de la prostate
IL255217A0 (en) Cancer neoepitopes
IL261468A (en) Uterine cancer treatments
IL255261A0 (en) Methods for treating cancer
SI3283527T1 (sl) Kombinirana terapija proti raku
IL277261A (en) Low molecular weight compounds for cancer treatment
PL3127187T3 (pl) Zespół antenowy
PT3197456T (pt) Tratamentos de cancro
IL263123A (en) Cancer treatments
IL265697B1 (en) Treatment of prostate cancer
IL264443A (en) Methods of treating prostate cancer
EP3322035A4 (fr) Antenne
DK3427339T3 (da) Antenne
PL3458052T3 (pl) Leczenie skojarzone nowotworu
EP3593139C0 (fr) Biomarqueurs du cancer
EP3413927A4 (fr) Cancérothérapie
DK3576740T3 (da) Cancerbehandling
MA53911A (fr) Polythérapie contre le cancer
EP3576791A4 (fr) Traitement du cancer à médiation par calréticuline
EP3310915A4 (fr) Immunothérapie tumorale
EP3591049A4 (fr) Variant du facteur (b) de limule
GB201814487D0 (en) Cancer
IL281281A (en) Combination therapy for the treatment of prostate cancer
GB201800733D0 (en) Cancer
MA42609A (fr) Polythérapie contre le cancer